HPGC(SH:600664) Zheng Quan Zhi Xing·2025-05-30 11:54Core Viewpoint - The company intends to sign a technology transfer contract with Shanghai Bozhi Research and Development Co., Ltd. to acquire the clinical approval for Daprodustat tablets, aiming to enhance its product portfolio and accelerate drug development and market entry [1][2]. Transaction Overview - The total contract amount is expected to be 44.8 million yuan, funded by the company's own resources [1]. - The contract does not require shareholder approval and does not constitute a related party transaction or a major asset restructuring [2]. Counterparty Information - Shanghai Bozhi Research and Development Co., Ltd. was established on October 16, 2020, with a registered capital of 50 million yuan [2]. - The company is engaged in medical research and technology services, with no existing relationships with the company in terms of ownership, business, or assets [2][3]. Transaction Target Information - Daprodustat is an oral medication for treating renal anemia, developed by GSK, and was first approved in Japan on June 29, 2020 [4]. - The ownership status of the clinical approval is clear, with no encumbrances or legal disputes affecting the transfer [4]. Pricing and Payment Structure - The estimated cost for self-research of the product is approximately 45.62 million yuan, making the negotiated contract price reasonable and lower than self-development costs [4][5]. - Payment will be made in eight installments linked to specific milestones in the contract [5]. Contractual Details - The contract includes the transfer of clinical approval and ongoing development services until the product is approved for market [5]. - Breach of contract terms will result in compensation for economic losses, with specific provisions for data integrity during regulatory reviews [5]. Impact on the Company - Signing the technology transfer contract is expected to accelerate drug development and enhance the company's competitive advantage and sustainable growth [6].